CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 937-945

  Chen, Po Chun ^a   Lin, Tien Huang ^b,c   Cheng, Hsu Chen ^a   Tang, Chih Hsin ^c,d  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b Buddhist Tzu Chi General Hospital Taichung Branch   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Fu Jen Catholic Uiversity   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN LINKED KINASE; INTERCELLULAR ADHESION MOLECULE 1; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CELL STIMULATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84859575254     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs108     Document Type: Article

References (42)

1. Bryant, R. J. et al. (2008) Screening for prostate cancer: an update. Eur. Urol., 53, 37-44.
2. Ernst, D. S. et al. (1991) Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta. J. Urol., 146, 372-376.
3. Perbal, B. (2004) CCN proteins: multifunctional signalling regulators. Lancet, 363, 62-64.
4. Planque, N. et al. (2003) A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int., 3, 15.
5. Chen, C. C. et al. (2009) Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol., 41, 771-783.
6. Lin, C. G. et al. (2003) CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J. Biol. Chem., 278, 24200-24208.
7. Lin, C. G. et al. (2005) Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J. Biol. Chem., 280, 8229-8237.
8. McCallum, L. et al. (2009) CCN3-a key regulator of the hematopoietic compartment. Blood Rev., 23, 79-85.
9. Perbal, B. et al. (2008) Prognostic value of CCN3 in osteosarcoma. Clin. Cancer Res., 14, 701-709.
10. Fukunaga-Kalabis, M. et al. (2008) Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene, 27, 2552-2560.
11. Maillard, M. et al. (2001) Differential expression of the ccn3 (nov) protooncogene in human prostate cell lines and tissues. Mol. Pathol., 54, 275-280.
12. Makrilia, N. et al. (2009) Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest., 27, 1023-1037.
13. Zimmerman, T. et al. (2008) Inhibitors targeting the LFA-1/ICAM-1 celladhesion interaction: design and mechanism of action. Curr. Pharm. Des., 14, 2128-2139.
14. Lawson, C. et al. (2009) ICAM-1 signaling in endothelial cells. Pharmacol. Rep., 61, 22-32.
15. van de Stolpe, A. et al. (1996) Intercellular adhesion molecule-1. J. Mol. Med. (Berl), 74, 13-33.
16. Duperray, A. et al. (1997) Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J. Biol. Chem., 272, 435-441.
17. Yang, S. F. et al. (2010) Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J. Biol. Chem., 285, 29808-29816.
18. Rauch, B. H. et al. (2007) ICAM-1 and p38 MAPK mediate fibrinogeninduced migration of human vascular smooth muscle cells. Eur. J. Pharmacol., 577, 54-57.
19. Roche, Y. et al. (2003) Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway. Thromb. Haemost., 89, 1089-1097.
20. Rosette, C. et al. (2005) Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis, 26, 943-950.
21. Grothey, A. et al. (1998) Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br. J. Cancer, 77, 801-807.
22. Benini, S. et al. (2005) In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene, 24, 4349-4361.
23. Tang, C. H. et al. (2008) Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis, 29, 35-43.
24. Huang, H. C. et al. (2003) Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. J. Biol. Chem., 278, 46750-46759.
25. Tseng, C. P. et al. (2003) Disabled-2 small interfering RNA modulates cellular adhesive function and MAPK activity during megakaryocytic differentiation of K562 cells. FEBS Lett., 541, 21-27.
26. Tseng, W. P. et al. (2010) Hypoxia induces BMP-2 expression via ILK, Akt, mTOR, and HIF-1 pathways in osteoblasts. J. Cell. Physiol., 223, 810-818.
27. Hsieh, M. T. et al. (2003) Differential gene expression of scopolamine-treated rat hippocampus-application of cDNA microarray technology. Life Sci., 73, 1007-1016.
28. Wang, Y. C. et al. (2003) Damage formation and repair efficiency in the p53 gene of cell lines and blood lymphocytes assayed by multiplex long quantitative polymerase chain reaction. Anal. Biochem., 319, 206-215.
29. Chiu, Y. C. et al. (2007) Stromal cell-derived factor-1 induces matrix metalloprotease-13 expression in human chondrocytes. Mol. Pharmacol., 72, 695-703.
30. Lin, C. C. et al. (2007) Transactivation of Src, PDGF receptor, and Akt is involved in IL-1beta-induced ICAM-1 expression in A549 cells. J. Cell. Physiol., 211, 771-780.
31. Lin, Y. C. et al. (2006) A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin. Cancer Res., 12, 7165-7173.
32. Yang, W. et al. (2011) Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell growth of the choriocarcinoma cell line Jeg3. Hum. Reprod., 26, 2850-2860.
33. Pfaff, M. et al. (1994) Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem., 269, 20233-20238.
34. Dedhar, S. et al. (1999) Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol., 9, 319-323.
35. Feeley, B. T. et al. (2006) Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone, 38, 154-166.
36. Perbal, B. et al. (2009) Prognostic relevance of CCN3 in Ewing sarcoma. Hum. Pathol., 40, 1479-1486.
37. Mundy, G. R. (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2, 584-593.
38. Heinlein, C. A. et al. (2004) Androgen receptor in prostate cancer. Endocr. Rev., 25, 276-308.
39. Terpstra, L. et al. (2003) Reduced chondrocyte proliferation and chondrodysplasia in mice lacking the integrin-linked kinase in chondrocytes. J. Cell Biol., 162, 139-148.
40. Chang, F. et al. (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia, 17, 590-603.
41. Inoue, J. et al. (2007) NF-kappaB activation in development and progression of cancer. Cancer Sci., 98, 268-274.
42. Le Dreau, G. et al. (2010) NOV/CCN3 upregulates CCL2 and CXCL1 expression in astrocytes through beta1 and beta5 integrins. Glia, 58, 1510-1521.